Article thumbnail

CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway

By Jianfeng Zheng, Rongquan Fu, Jing Li and Xiaozhong Wang
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3108921
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). AA: Targeting apoptosis pathways in cancer therapy.
  2. (2003). AF: Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett
  3. (2004). Akira S: TLR signaling pathways. Semin Immunol
  4. (2005). al: Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
  5. (1997). al: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med
  6. (2003). al: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
  7. (2010). al: Toll-like receptor 9-mediated inhibition of apoptosis occurs through suppression of FoxO3a activity and induction of FLIP expression. Exp Mol Med
  8. (2000). Bacterial CpGDNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins.
  9. (2003). CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol
  10. (2002). et al: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
  11. (1998). Factor VM: Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis
  12. (2001). Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice.
  13. (1998). Ohgaki H: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res
  14. (2004). Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.
  15. (2006). Quantitative real-time RT-PCR data analysis: current concepts and the novel “gene expression’s C (T) difference” formula.
  16. (2004). Siegel RM: Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol
  17. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
  18. (2001). Theise N: Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer
  19. (2004). Toge T: The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer
  20. (2003). Toll-like receptor signaling in anti-cancer immunity.
  21. (2002). Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol
  22. (2005). XY: Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin